ライフサイエンスコーパス: cytarabine

1 sive chemotherapy with an anthracycline plus cytarabine).

2 , mitoxantrone plus cytarabine, or high-dose cytarabine).

3 est supportive care with or without low-dose cytarabine.

4 , gemcitabine, fludarabine, chlorambucil, or cytarabine.

5 ilized the combination of anthracyclines and cytarabine.

6 e of anthracycline (or anthracenedione) plus cytarabine.

7 kemic activity, stronger than that caused by cytarabine.

8 ight (2%) of 350 patients given placebo plus cytarabine.

9 a liposomal preparation of daunorubicin and cytarabine.

10 and acts synergistically in combination with cytarabine.

11 imab and four doses of intrathecal liposomal cytarabine.

12 tance to gemcitabine and cross-resistance to cytarabine.

13 yme 1 (AK1) inactivates antimetabolites like Cytarabine.

14 on, or with secondary AML benefitted from HD cytarabine.

15 reached on the benefit of higher dosages of cytarabine.

16 for these exceptionally high-dose levels of cytarabine.

17 mission (CR) received 3 courses of high-dose cytarabine.

18 ents who received rituximab and/or high-dose cytarabine.

19 3 weeks; and 4 weeks of cyclophosphamide and cytarabine.

20 in relationship with variable dose levels of cytarabine.

21 val advantage equivalent to doxorubicin plus cytarabine.

22 ombination with mitoxantrone, etoposide, and cytarabine.

23 ed by current chemotherapeutic drugs such as cytarabine.

24 ressing AML cells to treatment with ATRA and cytarabine.

25 I-AML3 to all-trans retinoic acid (ATRA) and cytarabine.

26 ted in superior survival rates compared with cytarabine.

27 atment with the cytidine nucleoside analogue cytarabine.

28 eive either imatinib or interferon alfa plus cytarabine.

29 restored H3K36me3 levels and sensitivity to cytarabine.

30 Induction included cytarabine 1.5 g/m(2) by 24-h continuous infusion daily

31 ravenously (IV) daily x 3 (days 4 to 6), and cytarabine 1.5 g/m(2) IV as a continuous infusion daily

32 cycle; 70 mg/m(2) in subsequent cycles) plus cytarabine (1 g/m(2) intravenously on days 1-5) or place

33 ere similar between MACE/MidAc and high-dose cytarabine (1.5/3.0 g/m(2)), but cytarabine required les

34 nd one cycle of amsacrine (500 mg/m(2)) plus cytarabine (10 g/m(2); MAC/MAMAC/MAC).

35 ive two cycles of consolidation therapy with cytarabine 100 mg/m(2) daily for 5 days, etoposide 75 mg

36 , alternating idarubicin 8 mg/m(2) on day 1, cytarabine 100 mg/m(2) on days 1 to 5, and a regimen of

37 ncluded idarubicin 8 mg/m(2) on days 1 to 5, cytarabine 100 mg/m(2) on days 1 to 7, and lomustine 200

38 days of venetoclax combined with infusional cytarabine 100 mg/m(2) on days 1-5 and idarubicin 12 mg/

39 ) per day for 3 days and continuous-infusion cytarabine 100 mg/m(2) per day for 7 days.

40 ide 100 mg/m(2) twice daily (days -5 to -2), cytarabine 100 mg/m(2) twice daily (days -5 to -2), and

41 a single, standard induction with infusional cytarabine (100 mg/m(2) for 7 days) and daunorubicin (60

42 in (45 mg/m(2) per day on days 1, 2, and 3), cytarabine (100 mg/m(2) per day by continuous infusion o

43 ction chemotherapy of continuous infusion of cytarabine (100 mg/m(2) per day on days 1-7) and intrave

44 In the second cycle, patients received cytarabine 1000 mg/m(2) twice daily on days 1-6 with or

45 r day), etoposide (100 mg/m(2) per day), and cytarabine (1000 mg/m(2) per day on days 1-5 of up to tw

46 e 360 mg/m(2) (maximum 600 mg) combined with cytarabine (1000 mg/m(2) per dose for eight doses), with

47 two cycles of mitoxantrone (30 mg/m(2)) plus cytarabine (12 g/m(2)) and one cycle of amsacrine (500 m

48 ses of methotrexate 3.5 g/m(2) on day 1 plus cytarabine 2 g/m(2) twice daily on days 2 and 3 (group A

49 ses of methotrexate 3.5 g/m(2) on day 1 plus cytarabine 2 g/m(2) twice daily on days 2 and 3 (group A

50 Fludarabine 30 mg/m(2) and cytarabine 2 g/m(2) were administered on days 15 to 19.

51 o courses of consolidation chemotherapy with cytarabine 2 gm/m(2) on days 1 through 5 with bortezomib

52 AG [fludarabine 30 mg/m(2)/dose on days 1-5; cytarabine 2,000 mg/m(2)/dose on days 1-5; and granulocy

53 w-dose cytarabine (subcutaneous injection of cytarabine 20 mg twice daily on days 1-10 of 28-day cycl

54 f intravenous rituximab 375 mg/m(2) (day 1), cytarabine 3 g/m(2) (days 2 and 3), and thiotepa 40 mg/m

55 cycles of R-AraC (rituximab 375 mg/m(2) D1, cytarabine 3 g/m(2) D1 to D2).

56 ngle hNT type (hENT1), accumulation of [(3)H]cytarabine, [(3)H]cladribine, or [(3)H]fludarabine was r

57 uded high-dose methotrexate (48%), high-dose cytarabine (33%), brain radiation (24%) and/or rituximab

58 18 showed association (P < .05) with either cytarabine 50% inhibitory concentration in leukemia cell

59 ontaining daunorubicin and intermediate-dose cytarabine (500 mg/m(2) every 12 hours for 6 days).

60 and prednisone) alternating with R-high-dose cytarabine (6 cycles total), followed by high-dose BEAM/

61 ns led to resistance to DNA-damaging agents, cytarabine, 6-thioguanine, doxorubicin, and etoposide, b

62 mly assigned to receive interferon alfa plus cytarabine (65.6%) and the short duration of therapy bef

63 No comparable activity is observed with cytarabine, a cytidine analogue without DNA-hypomethylat

64 h decitabine, a DNA demethylating agent, and cytarabine, a frontline cytotoxic agent used in the trea

65 (60 mg/m(2) per day on days 1, 2, and 3) and cytarabine alone (DA).

66 % (14-31) of those treated with methotrexate-cytarabine alone (hazard ratio 0.46, 95% CI 0.28-0.74) a

67 n reducing tumour burden than treatment with cytarabine alone suggesting that the sequential delivery

68 AEs were similar for decitabine and cytarabine, although patients received a median of four

69 f ROS levels and sensitivity of AML cells to cytarabine, an essential chemotherapeutic backbone in th

70 on chemotherapy with 7 days of standard-dose cytarabine and 3 days of an anthracycline ("7+3") CLAG-M

71 s 38.7% for patients randomly assigned to SD cytarabine and 42.5% for those randomly assigned to HD c

72 receive up to four consolidation cycles with cytarabine and alisertib, and alisertib maintenance for

73 onsolidation courses that included high-dose cytarabine and anthracycline, and maintenance therapy co

74 eplication stress, diminishes sensitivity to cytarabine and anthracyclines as single agents, suggesti

75 cell-differentiating drugs/compounds such as cytarabine and aphidicolin and found that they also prim

76 , the IC(50) of FdUMP[10] was lower than for cytarabine and approximately 1000 times lower than 5-flu

77 apy (induction therapy with daunorubicin and cytarabine and consolidation therapy with high-dose cyta

78 liposomally encapsulated 5:1 molar ratio of cytarabine and daunorubicin that recently received regul

79 re achieved among the 31 patients with prior cytarabine and daunorubicin treatment.

80 Adverse events were consistent with cytarabine and daunorubicin treatment.

81 sing a 3 + 7 regimen including standard-dose cytarabine and daunorubicin, complete remission was achi

82 e]) followed by intensification 1 (high-dose cytarabine and etoposide), intensification 2 (high-dose

83 osis and DNA damage following treatment with cytarabine and idarubicin.

84 20 (6%) of 355 patients given vosaroxin plus cytarabine and in eight (2%) of 350 patients given place

85 al doses]), and intensification 3 (high-dose cytarabine and l-asparaginase).

86 and etoposide), intensification 2 (high-dose cytarabine and mitoxantrone [12 mg/m(2)/dose daily; four

87 We report results of a phase 2 trial using cytarabine and rituximab as induction regimen before aut

88 ents in first complete remission (CR1) after cytarabine and standard- or high-dose daunorubicin induc

89 tudies confirmed OCTN1-mediated transport of cytarabine and various structurally related cytidine ana

90 nvolving combinations of Mnk inhibitors with cytarabine and/or mTOR inhibitors for the treatment of A

91 Median half-life was 31.1 hours (cytarabine) and 21.9 hours (daunorubicin), with both dru

92 odeficient mouse response to combined Ara-C (cytarabine) and doxorubicin treatment.

93 therapy induction (rituximab, dexamethasone, cytarabine, and a platinum derivative [R-DHAP]), the ove

94 receive 2 induction cycles with idarubicin, cytarabine, and all-trans retinoic acid either with VPA

95 Despite immunochemotherapy, high-dose cytarabine, and ASCT, younger MCL patients with deletion

96 Cyclophosphamide, systemic cytarabine, and central nervous system radiotherapy were

97 one, and cisplatin (GDP) with dexamethasone, cytarabine, and cisplatin (DHAP) before ASCT.

98 latin, and etoposide (ICE) or dexamethasone, cytarabine, and cisplatin (DHAP), with autologous transp

99 to induction chemotherapy with mitoxantrone, cytarabine, and etoposide preceded, or not, by a course

100 rabine, followed by R-HDS (cyclophosphamide, cytarabine, and etoposide) supported by autologous stem-

101 ients were randomly assigned to fludarabine, cytarabine, and granulocyte colony-stimulating factor (F

102 r cells after administration of clofarabine, cytarabine, and granulocyte-colony stimulating factor pr

103 omparator group of supportive care, low-dose cytarabine, and intensive cytarabine plus anthracycline,

104 s were prepared using carmustine, etoposide, cytarabine, and melphalan and received consistent manage

105 h-dose treatment with carmustine, etoposide, cytarabine, and melphalan as well as rabbit antithymocyt

106 AM/C (bis-chloroethylnitrosourea, etoposide, cytarabine, and melphalan or cyclophosphamide) and autol

107 tion stress and damage by ATR inhibition and cytarabine, and the ability of ATR inhibition to abrogat

108 ing tumor cells were also cross-resistant to cytarabine, another nucleoside analog commonly used in c

109 ic stem-cell transplantation, cladribine and cytarabine, anti-MEK agent, vinblastine, etc) used for m

110 High-dose cytarabine applied during remission induction or as cons

111 e to docetaxel, paclitaxel, vincristine, and cytarabine (Ara-C) and exhibited increased cellular drug

112 TNAs, including 2',3'-dideoxycytidine (ddC), cytarabine (ara-C) and zidovudine (Azidothymidine, AZT).

113 The nucleoside analog cytarabine (Ara-C) is an essential component of primary

114 and enhanced the antileukemic properties of cytarabine (Ara-C) or mammalian target of rapamycin (mTO

115 from deep-sequencing of RNA derived from two cytarabine (Ara-C) resistance acute myeloid leukemia (AM

116 ional phase 2 study combining cladribine and cytarabine (Ara-C) was initiated for patients with refra

117 duction therapy commenced with daunorubicin, cytarabine (Ara-C), and all-trans retinoic acid (ATRA),

118 ntify rational therapeutic combinations with cytarabine (Ara-C), we developed a high-throughput, smal

119 g the effects of four CTNAs-acyclovir (ACV), cytarabine (Ara-C), zidovudine (AZT) and zalcitabine (dd

120 of acute myeloid leukaemia (AML) patients to cytarabine (Ara-C)-based therapies are often short lived

121 in clinical therapy: daunorubicin (DNR) and cytarabine (ara-C).

122 eukemia (AML) cells for cytotoxic killing by cytarabine (Ara-C).

123 In vitro data suggested synergy with cytarabine (Ara-C).

124 rapeutic agents, i.e., doxorubicin (DOX) and cytarabine (Ara-C).

125 e metabolite of cytosine arabinoside (ara-C, cytarabine), ara-CTP, has been investigated and verified

126 duction (3 + 7) and consolidation (high-dose cytarabine; Ara-C) as the standard of care for acute mye

127 n species (ROS)-inducing chemotherapy agents cytarabine (AraC) and daunorubicin (DNR), a phenomenon b

128 cells ex vivo have increased sensitivity to cytarabine (araC) and daunorubicin, suggesting that opti

129 tochondrial and cytosolic ROS in response to cytarabine (AraC) and overexpressed myeloperoxidase (MPO

130 Cytarabine (AraC) is the mainstay chemotherapy for acute

131 Cytarabine (AraC) is the mainstay for the treatment of a

132 Cytarabine (AraC) represents the most effective single a

133 1-Beta-D-arabinofuranosylcytosine (cytarabine, araC) and 2',2'-difluoro-2'-deoxycytidine (g

134 solidation with dasatinib, sequentially with cytarabine, asparaginase, and methotrexate for 6 months.

135 Cytarabine at 1.5 g/m(2) is equivalent to a 3 g/m(2) dos

136 Most centers use 7 to 10 days of cytarabine at a daily dose of 100 to 200 mg/m(2) for rem

137 If the same anthracycline/cytarabine-based approach is deployed, the remission rat

138 y confirms that induction with rituximab and cytarabine-based regimens is safe and effective in MCL p

139 ade, there has been a widespread adoption of cytarabine-based therapy in younger patients, and the in

140 itive/synergistic effects when combined with cytarabine, bendamustine, or rituximab.

141 ective relative to the AML standard of care, cytarabine, both in vitro and in vivo.

142 al transplant regimen, fludarabine/amsacrine/cytarabine-busulphan (FLAMSA-Bu), but the impact of this

143 h MACE/MidAc is similar overall to high-dose cytarabine, but superior in high-risk patients.

144 y used in cancer therapy, and 4-(N)-stearoyl cytarabine carried by solid lipid nanoparticles can also

145 When cytarabine chemotherapy was administered prior to vaccin

146 The combination of ADI-PEG 20 and cytarabine chemotherapy was more effective than either t

147 ux of anticancer nucleoside drugs, including cytarabine, cladribine, and fludarabine.

148 randomly assigned to receive clofarabine and cytarabine (Clo+AraC, n = 129) or high-dose cytarabine,

149 trexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for HIV-positive patients.

150 mab with or without thiotepa to methotrexate-cytarabine combination therapy (the MATRix regimen), fol

151 r ABT-199 to synergize with tivantinib while cytarabine combination with tivantinib was antagonistic.

152 induction chemotherapy with an anthracycline/cytarabine combination, followed by either consolidation

153 sponded to the combination of bortezomib and cytarabine, concomitant with the re-establishment of EZH

154 rd induction course, followed by 3 high-dose cytarabine consolidation courses.

155 agnosis to receive either standard high-dose cytarabine consolidation with three cycles of 18 g/m(2)

156 0 mg/m(2) for patients aged >60 years], plus cytarabine continuous intravenous infusion on days 1-7 [

157 a liposomal formulation of daunorubicin and cytarabine (CPX-351).

158 lodysplastic syndromes, that is, idarubicine-cytarabine (cycle I) and amsacrine-cytarabine (cycle II)

159 arubicine-cytarabine (cycle I) and amsacrine-cytarabine (cycle II) without or with clofarabine (10 mg

160 Cytarabine (cytosine arabinoside) is one of the most eff

161 to two induction courses of daunorubicin and cytarabine (DA) with or without etoposide (ADE; n = 1983

162 ee induction regimens: DA (daunorubicin plus cytarabine), DAC (DA plus cladribine), or DAF (DA plus f

163 dies and those receiving SOC (induction with cytarabine + daunorubicin (7 + 3 or equivalent) or hypom

164 AML samples in vivo, and more effective than cytarabine + daunorubicin chemotherapy.

165 Importantly, while cytarabine + daunorubicin enriched for AML stem cells, e

166 ednisone), CALGB C9710 (single arm of ATRA + cytarabine + daunorubicin), Eastern Cooperative Oncology

167 d SWOG S0521 (single-arm induction of ATRA + cytarabine + daunorubicin).

168 cytarabine (Clo+AraC, n = 129) or high-dose cytarabine, daunorubicin, and etoposide (HD-ADE, n = 133

169 rapies for mutant FLT3 and IDH2, a liposomal cytarabine-daunorubicin formulation for therapy-related

170 proved overall survival compared to standard cytarabine/daunorubicin therapy.

171 60 years) de novo CN-AML patients treated on cytarabine/daunorubicin-based protocols.

172 CPX-351 is a liposomal formulation of cytarabine:daunorubicin designed to deliver synergistic

173 s of venetoclax (days -6 to 7) combined with cytarabine (days 1-2) and idarubicin (day 1).

174 of dexamethasone, etoposide, cisplatin, and cytarabine (DECA).

175 and amsacrine in combination with high-dose cytarabine does not improve treatment outcome and confer

176 ngs suggest that the use of clofarabine with cytarabine during remission induction might reduce the n

177 seen in patients treated with escalated-dose cytarabine during remission induction.

178 high-dose consolidation with etoposide plus cytarabine (EA); three, progression-free survival (PFS);

179 higher remission and survival rates than SD cytarabine, especially in patients younger than age 46 y

180 front for induction therapy with idarubicin, cytarabine, etoposide, and all-trans-retinoic acid with

181 sisted of two cycles of remission induction (cytarabine, etoposide, and daunorubicin [50 mg/m(2) x 3

182 icin (FLAG-Ida; n = 1268), and to amsacrine, cytarabine, etoposide, and then mitoxantrone/cytarabine

183 alternating with high-dose methotrexate and cytarabine every 21 days.

184 ved 2 cycles of consolidation with high-dose cytarabine followed by peripheral blood progenitor cell

185 treated with high-doses of methotrexate and cytarabine, followed by R-HDS (cyclophosphamide, cytarab

186 a reappraisal of the usefulness of high-dose cytarabine for acute myeloid leukemia treatment.

187 n the SELHEM (Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leuke

188 f clinically used pyrimidine-based prodrugs (cytarabine, gemcitabine).

189 e (ADE; n = 1983) or ADE versus fludarabine, cytarabine, granulocyte colony-stimulating factor, and i

190 ycline ("7+3") CLAG-M (cladribine, high-dose cytarabine, granulocyte colony-stimulating factor, and m

191 us cytarabine group than in the placebo plus cytarabine group (107 [30%] of 356 patients vs 58 [16%]

192 and 6.1 months (5.2-7.1) in the placebo plus cytarabine group (hazard ratio 0.87, 95% CI 0.73-1.02; u

193 onths (95% CI 6.4-8.5) in the vosaroxin plus cytarabine group and 6.1 months (5.2-7.1) in the placebo

194 us cytarabine group than in the placebo plus cytarabine group included febrile neutropenia (167 [47%]

195 hat were more frequent in the vosaroxin plus cytarabine group than in the placebo plus cytarabine gro

196 ved complete remission in the vosaroxin plus cytarabine group than in the placebo plus cytarabine gro

197 8 [8%] of 355 patients in the vosaroxin plus cytarabine group vs 23 [7%] of 350 in the placebo plus c

198 group vs 23 [7%] of 350 in the placebo plus cytarabine group; 60-day: 70 [20%] vs 68 [19%]).

199 nation (CLARA) versus conventional high-dose cytarabine (HDAC) as postremission chemotherapy in young

200 CT and 22 after consolidation with high-dose cytarabine (HiDAC).

201 cts of ATR inhibition alone or combined with cytarabine in AML cells.

202 tivity of ATR inhibition in combination with cytarabine in AML.

203 otherapeutic and >100-fold dose reduction of cytarabine in both AML cell lines and primary T-ALL cell

204 tients) versus escalated-dose (207 patients) cytarabine in cycles 1 and 2.

205 nical leukemia therapeutics daunorubicin and cytarabine in in vitro cellular models of AML and primar

206 G2/M cell cycle arrest, and cooperated with cytarabine in inducing DNA replication stress and damage

207 ion with hypomethylating agents and low-dose cytarabine in older adults for whom chemotherapy is not

208 tion with hypomethylating agents or low-dose cytarabine in older patients.

209 continuously exposed to increasing doses of cytarabine in order to establish equivalent resistant ce

210 ion with hypomethylating agents and low-dose cytarabine in patients with high-risk myelodysplastic sy

211 mab to frontline therapy with idarubicin and cytarabine in patients with newly diagnosed acute myeloi

212 -class anticancer quinolone derivative, plus cytarabine in patients with relapsed or refractory acute

213 ortezomib was combined with daunorubicin and cytarabine in previously untreated older adults with acu

214 d-dose whole-brain radiotherapy (rdWBRT) and cytarabine in primary CNS lymphoma.

215 he standard combination of anthracycline and cytarabine in primary patient xenografts.

216 cs to matched patients treated with low-dose cytarabine in the United Kingdom AML14 trial, but had si

217 nical observation of superiority of HMA over cytarabine in this difficult-to-treat patient group.

218 primary human AML cells after treatment with cytarabine in vitro Upon overexpression, RUNX1 restricte

219 nd autologous stem-cell rescue and high-dose cytarabine in younger patients and the benefits of maint

220 r export, when combined with fludarabine and cytarabine, in children with relapsed or refractory leuk

221 plantation (ASCT), with or without high-dose cytarabine, in the randomized European MCL Younger trial

222 ein, include tumor lysis, hyperleukocytosis, cytarabine-induced cellebellar toxicity, acute promyeloc

223 LCLs with AA genotype were more sensitive to cytarabine-induced cytotoxicity (P = 1.31 x 10(-6)) and

224 d to investigate the genetic determinants of cytarabine-induced cytotoxicity.

225 AZ20 synergistically enhanced cytarabine-induced proliferation inhibition and apoptosi

226 feration inhibition and apoptosis, abolished cytarabine-induced S and G2/M cell cycle arrest, and coo

227 ortezomib to standard 3 + 7 daunorubicin and cytarabine induction chemotherapy for AML resulted in an

228 chemotherapy consisting of intermediate-dose cytarabine (Int-DAC).

229 us infusion 30 mg/m(2) per day on days 2-6), cytarabine (intravenous infusion 2000 mg/m(2) per day on

230 Cytarabine is a key constituent of remission induction c

231 R-MPV combined with consolidation rdWBRT and cytarabine is associated with high response rates, long-

232 o induction chemotherapy with idarubicin and cytarabine is feasible in patients with newly diagnosed

233 ombination of vorinostat with idarubicin and cytarabine is safe and active in AML.

234 orafenib in combination with clofarabine and cytarabine is tolerable and shows activity in relapsed/r

235 linexor, in combination with fludarabine and cytarabine, is tolerable at doses up to 55 mg/m(2) in pe

236 lymphoma-2 inhibitor, together with low-dose cytarabine (LDAC) in older adults with AML.

237 ntensive induction therapy compared low-dose cytarabine (LDAC) with or without volasertib, a highly p

238 and 42.5% for those randomly assigned to HD cytarabine (log-rank test P = .06; multivariable analysi

239 cytarabine, etoposide, and then mitoxantrone/cytarabine (MACE-MidAC) or high-dose cytarabine (n = 1,4

240 ent AHSCT using BEAM (carmustine, etoposide, cytarabine, melphalan)+antithymocyte globulin chemothera

241 ed autologous SCT after carmustine-etoposide-cytarabine-melphalan.

242 s suggests that the addition of vosaroxin to cytarabine might be of clinical benefit to some patients

243 The cytarabine MTD used in stage two was 800 mg/m(2), and R-

244 y 1), B (70 mg/m(2) IV on days 2 and 3), and cytarabine (MTD IV on days 2 to 4) every 28 days for fou

245 ed AML salvage regimens, including high-dose cytarabine, multiagent chemotherapy, hypomethylating age

246 antrone/cytarabine (MACE-MidAC) or high-dose cytarabine (n = 1,445) 3 g/m(2) or 1.5 g/m(2) (n = 657)

247 oxin plus cytarabine (n=356) or placebo plus cytarabine (n=355).

248 nts were randomly assigned to vosaroxin plus cytarabine (n=356) or placebo plus cytarabine (n=355).

249 alternating with high-dose methotrexate and cytarabine on courses 2, 4, 6, and 8.

250 oxic activities of standard AML chemotherapy cytarabine or daunorubicin.

251 Consolidation with high-dose cytarabine or stem-cell transplantation in high-risk pat

252 onsolidation, and finally to a fifth course (cytarabine) or not (n = 227).

253 cycles of attenuated doses of idarubicin and cytarabine, or allogeneic stem cell transplantation if e

254 gimens contained busulfan, cyclophosphamide, cytarabine, or fludarabine according to the donor used.

255 colony-stimulating factor, mitoxantrone plus cytarabine, or high-dose cytarabine).

256 and subsequent treatment with bendamustine, cytarabine, or lenalidomide failed to reveal any associa

257 Cytarabine plays a pivotal role in the treatment of pati

258 alternating with methotrexate and high-dose cytarabine plus a tyrosine kinase inhibitor, had minimal

259 ive care, low-dose cytarabine, and intensive cytarabine plus anthracycline, while inducing trilineage

260 randomized to receive low-dose or high-dose cytarabine plus daunorubicin and etoposide; of these, 18

261 FdUMP[10] was better tolerated than 5-FU or cytarabine plus doxorubicin and did not affect normal HS

262 ]) or standard care (either fludarabine plus cytarabine plus granulocyte colony-stimulating factor, m

263 % (21-42) of those treated with methotrexate-cytarabine plus rituximab (0.61, 0.40-0.94).

264 equent in patients treated with methotrexate-cytarabine plus rituximab and thiotepa, but infective co

265 ine and consolidation therapy with high-dose cytarabine) plus either midostaurin or placebo; those wh

266 HD cytarabine produces higher remission and survival rates

267 population and alone or in combination with Cytarabine, prolonged survival in mouse model of human l

268 mg/m(2) or 360 mg/m(2), in combination with cytarabine received intravenously every 12 h at either 1

269 er, patients treated with the escalated-dose cytarabine regimen benefited from G-CSF priming, with im

270 406 patients were also randomized between 2 cytarabine regimens comparing conventional-dose (199 pat

271 ined with hypomethylating agents or low-dose cytarabine represents an important new therapy for older

272 d high-dose cytarabine (1.5/3.0 g/m(2)), but cytarabine required less supportive care.

273 ells, and predict relapse based on increased cytarabine resistance of a KRAS wild-type subclone.

274 Our data indicate that cytarabine-resistant cells are more susceptible to natur

275 arly, the combination of cercosporamide with cytarabine resulted in enhanced antileukemic responses i

276 ess let-7a exhibited enhanced sensitivity to cytarabine, resulting in greatly extended survival of im

277 th poor or no response to regimens including cytarabine, rituximab, and autologous stem-cell transpla

278 -5 and 0 (group B); or the same methotrexate-cytarabine-rituximab combination plus thiotepa 30 mg/m(2

279 -5 and 0 (group B); or the same methotrexate-cytarabine-rituximab combination plus thiotepa 30 mg/m(2

280 ediated cell lysis as compared with parental cytarabine-sensitive cells.

281 ted total body irradiation, race, and use of cytarabine significantly increased the incidence of cata

282 selected chemotherapy: subcutaneous low-dose cytarabine (subcutaneous injection of cytarabine 20 mg t

283 isation have demonstrated that methotrexate, cytarabine, thiotepa, and rituximab (called the MATRix r

284 ) intravenously on days 1-5) or placebo plus cytarabine through a central interactive voice system wi

285 h AK1 levels correlate with poor survival of Cytarabine-treated acute myeloid leukemia patients, qual

286 MCC expression was induced by cytarabine treatment from 1.7- to 26.6-fold in LCLs.

287 F9-induced leukemia and caused resistance to cytarabine treatment in vivo, whereas homozygous loss de

288 The combination of CXCR4 silencing and cytarabine treatment resulted in more effective cytotoxi

289 ents without G-CSF undergoing escalated-dose cytarabine treatment.

290 the Miz-1 POZ domain enhanced the effect of cytarabine treatment.

291 atients receiving FLAG-Ida (two courses) and cytarabine (two courses), 8-year survival was 63% for pa

292 atinib and dasatinib inhibit fludarabine and cytarabine uptake.

293 elacytarabine, a novel elaidic acid ester of cytarabine, versus the investigator's choice of one of s

294 tergroup I0129, consisting of daunorubicin + cytarabine vs ATRA), and SWOG S0521 (single-arm inductio

295 nivolumab in combination with idarubicin and cytarabine was done at the University of Texas MD Anders

296 Sequential treatment with decitabine and cytarabine was found to be more effective in reducing tu

297 Consolidation cytarabine was given after the radiotherapy.

298 c antileukemic interactions between AZ20 and cytarabine were confirmed in primary AML patient samples

299 In this phase II study, we combined cytarabine with R and B (R-BAC) in patients with MCL age

300 including methotrexate, hydrocortisone, and cytarabine would improve the postinduction 5-year diseas